CN105111137B - 苯磺酸左旋氨氯地平晶体、其制备方法和应用 - Google Patents
苯磺酸左旋氨氯地平晶体、其制备方法和应用 Download PDFInfo
- Publication number
- CN105111137B CN105111137B CN201510519007.9A CN201510519007A CN105111137B CN 105111137 B CN105111137 B CN 105111137B CN 201510519007 A CN201510519007 A CN 201510519007A CN 105111137 B CN105111137 B CN 105111137B
- Authority
- CN
- China
- Prior art keywords
- crystal
- levamlodipine besylate
- preparation
- levamlodipine
- besylate crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 111
- 229950008554 levamlodipine Drugs 0.000 title claims abstract description 88
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 title claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 238000002050 diffraction method Methods 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- 230000001631 hypertensive effect Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 23
- 239000000843 powder Substances 0.000 abstract description 10
- 229910017488 Cu K Inorganic materials 0.000 abstract description 8
- 229910017541 Cu-K Inorganic materials 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- ZPBWCRDSRKPIDG-LMOVPXPDSA-N benzenesulfonic acid;3-o-ethyl 5-o-methyl (4s)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-LMOVPXPDSA-N 0.000 description 65
- 229940079593 drug Drugs 0.000 description 23
- 238000000034 method Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 238000002447 crystallographic data Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 3
- 229960004005 amlodipine besylate Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011549 crystallization solution Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011175 product filtration Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510519007.9A CN105111137B (zh) | 2015-08-21 | 2015-08-21 | 苯磺酸左旋氨氯地平晶体、其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510519007.9A CN105111137B (zh) | 2015-08-21 | 2015-08-21 | 苯磺酸左旋氨氯地平晶体、其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105111137A CN105111137A (zh) | 2015-12-02 |
CN105111137B true CN105111137B (zh) | 2016-04-27 |
Family
ID=54659293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510519007.9A Active CN105111137B (zh) | 2015-08-21 | 2015-08-21 | 苯磺酸左旋氨氯地平晶体、其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105111137B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111689894B (zh) * | 2019-03-13 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种苯磺酸左旋氨氯地平晶型 |
CN112110850B (zh) * | 2019-06-20 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种苯磺酸左旋氨氯地平新晶型 |
CN110372576A (zh) * | 2019-07-10 | 2019-10-25 | 复旦大学 | 一种钙通道阻滞药物分子共晶体及其制备方法 |
CN110372575A (zh) * | 2019-07-10 | 2019-10-25 | 复旦大学 | 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用 |
CN110882249B (zh) | 2019-11-08 | 2021-04-30 | 北京吾为尔创科技有限公司 | 含苯磺酸左氨氯地平水合物的组合物及其制备方法 |
CN113087656B (zh) * | 2020-01-09 | 2024-05-07 | 鲁南制药集团股份有限公司 | 一种无定型苯磺酸左旋氨氯地平 |
CN112022849A (zh) * | 2020-05-17 | 2020-12-04 | 复旦大学 | 富马酸左旋氨氯地平共晶药物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355162A (zh) * | 2001-11-22 | 2002-06-26 | 张喜田 | 可生成水合物的左旋氨氯地平盐和其水合物及其制剂 |
KR20120066691A (ko) * | 2010-09-15 | 2012-06-25 | 대화제약 주식회사 | 에스-암로디핀 베실레이트 및 그 수화물의 제조방법 |
-
2015
- 2015-08-21 CN CN201510519007.9A patent/CN105111137B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1355162A (zh) * | 2001-11-22 | 2002-06-26 | 张喜田 | 可生成水合物的左旋氨氯地平盐和其水合物及其制剂 |
KR20120066691A (ko) * | 2010-09-15 | 2012-06-25 | 대화제약 주식회사 | 에스-암로디핀 베실레이트 및 그 수화물의 제조방법 |
Non-Patent Citations (1)
Title |
---|
Phase transformations of amlodipine besylate solid forms;VISHAL KORADIA;《Journal of Pharmaceutical Sciences》;20110222;第100卷(第7期);第2896~2910页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105111137A (zh) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105111137B (zh) | 苯磺酸左旋氨氯地平晶体、其制备方法和应用 | |
Bernasconi et al. | Selective synthesis of a salt and a cocrystal of the ethionamide–salicylic acid system | |
Chandel et al. | Co-crystalization of aceclofenac and paracetamol and their characterization. | |
CN102702008B (zh) | 阿戈美拉汀硫酸复合物及其制备方法 | |
CN101801381A (zh) | 新型氨基甲酰基-环己烷衍生物的溶剂合物和结晶形式 | |
TWI727314B (zh) | 盛格列汀的鹽、其製備方法與用途以及藥物組合物 | |
Quinn et al. | Fast 19F Magic-angle spinning nuclear magnetic resonance for the structural characterization of active pharmaceutical ingredients in blockbuster drugs | |
Budiman et al. | Enhancement of solubility and dissolution rate of glibenclamide by cocrystal approach with solvent drop grinding method | |
Bruni et al. | Multicomponent crystals of gliclazide and tromethamine: preparation, physico-chemical, and pharmaceutical characterization | |
WO2021004209A1 (zh) | 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用 | |
CN102942576B (zh) | 头孢米诺钠新晶型组合物及其制备方法 | |
CN104447771A (zh) | 一种稳定的马来酸阿塞那平化合物 | |
CN107721839A (zh) | 姜黄素‑4‑氨基苯酚共晶及其制备方法 | |
CN110372576A (zh) | 一种钙通道阻滞药物分子共晶体及其制备方法 | |
CN103025753A (zh) | 晶体盐酸依泽替米贝非溶剂化物 | |
CN104649969A (zh) | 一种替尼类药物的盐及其制备方法 | |
CN103951654A (zh) | 甲磺酸达比加群酯的晶体v及其制备方法 | |
JPWO2004076460A1 (ja) | イリノテカン塩酸塩の結晶多形の製造方法 | |
CN103804366B (zh) | 一种拉呋替丁晶型化合物 | |
CN111671750A (zh) | 结晶于三斜晶系的马来酸左旋氨氯地平共晶药物及其制备方法和应用 | |
CN112022849A (zh) | 富马酸左旋氨氯地平共晶药物及其制备方法和应用 | |
CN113402458A (zh) | 一种恩诺沙星共晶及其制备方法 | |
CN105503888B (zh) | 一种盐酸纳洛酮晶型化合物 | |
Mishra et al. | Novel synthetic as well as natural auxiliaries with a blend of NMR methodological developments for chiral analysis in isotropic media | |
Shen et al. | Structural analysis and properties of three novel sulfonic acid-based pharmaceutical salts of paliperidone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151202 Assignee: Shihuida Pharma Group (Jilin) Co., Ltd. Assignor: Xue Chuanxiao Contract record no.: 2018220000004 Denomination of invention: Levamlodipine besylate crystal and preparation method and application thereof Granted publication date: 20160427 License type: Exclusive License Record date: 20180801 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211012 Address after: 130102 No. 2, Jierui Road, Kangning, Jiutai Economic Development Zone, Changchun City, Jilin Province (No. 1898, Jichang Road) Patentee after: Feiyang Biotechnology (Jilin) Co.,Ltd. Address before: 200433 floor 5, jinzuo, Fortune International Plaza, No. 39, Guoquan Road, Yangpu District, Shanghai Patentee before: Xue Chuanxiao |